Summary of new pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022. ADHF, acute decompensated heart failure; ASCVD, atherosclerotic cardiovascular disease; ATPase, adenosine triphosphatase; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1; HF, heart failure; HFmrEF, HF with mildly reduced ejection fraction; HFpEF, HF with preserved ejection fraction; HFpEF, heart failure with preserved ejection fraction; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; oHCM, obstructive hypertrophic cardiomyopathy; SGLT2Is, sodium-glucose cotransporter-2 inhibitors; siRNA, small interfering RNA; T2DM, type 2 diabetes mellitus.